Crispr Therapeutics price target lowered to $49 from $53 at Stifel

Stifel analyst Benjamin Burnett lowered the firm’s price target on Crispr Therapeutics (CRSP) to $49 from $53 and keeps a Hold rating on the shares. The firm’s neutral thesis on the stock is largely predicated on the view that the Casgevy launch will be slow to inflect, but it sees a few pipeline updates that “we think have the potential to reinvigorate sentiment,” the analyst tells investors.